

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Moussaoui-Mrabet et al.

Examiner: **Falk, Anne Marie**

Art Unit: **1632**

Application No.: **10/088,138**

Filed: **November 25, 2002**

Title: **NOVEL ANIMAL MODEL OF
ALZHEIMER DISEASE WITH
AMYLOID PLAQUES AND
MITOCHONDRIAL DYSFUNCTION**

RESPONSE TO OFFICE COMMUNICATION

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Communication dated May 5, 2006, setting forth a requirement for restriction in the above-referenced application, Applicants provisionally elect, with **traverse**, Group I, claims 1-10 and 13, drawn to i) a non-human transgenic animal model of Alzheimer's disease which exhibits both amyloid plaques and mitochondrial dysfunction, and ii) a method for identifying compounds for treating neurodegenerative diseases using the transgenic animal model.

The Examiner furthermore required Applicants under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims should be restricted if no generic claim is finally held to be allowable. In the claims which are directed to a plurality of mutations in the APP gene, Applicants elected a specific combination of any of Swedish, London and Dutch mutations (d). Applicants also elect the M146L for PS1 gene (e).

Applicants reserve the right to file one or more divisional applications directed to the non-elected subject matter in this application.

Please consider the Remarks beginning on page 2 of this paper.